Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Genitourinary 2Gastrointestinal 2Plasma cell 1Gynecologic 1Dermatologic 1Classical hematology 1

Conditions

Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Carboplatin 62Paclitaxel 61Specimen Handling 37Cisplatin 37Taxes 35Magnetic Resonance Spectroscopy 31Bevacizumab 30Immunoglobulin G 23Disulfides 23Biopsy 22Cyclophosphamide 19aldesleukin 17Topotecan 16Brachytherapy 16Radiotherapy 15Gemcitabine 15veliparib 14Oxaliplatin 13Doxorubicin 13temsirolimus 12fludarabine 12Platinum 12Docetaxel 121,2-diaminocyclohexaneplatinum II citrate 12olaparib 11liposomal doxorubicin 10cediranib 10Sirolimus 10Radiation 9Nivolumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Bryostatins × Gynecologic × Clear all
NCT00006942 2013-08-26

Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
32 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡